A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...

Please provide your email address to receive an email when new articles are posted on . Within the studied cohort, males had a higher IPF death rate than females. Researchers observed eight industries ...

Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited ...

A data analysis found the inhaled therapy Tyvaso outperformed a placebo at preserving lung function in people with IPF in a ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...

The actor tells AARP about her mom’s struggle with pulmonary fibrosis and the warning signs that might help others get an ...

DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...

Please provide your email address to receive an email when new articles are posted on . Both the 18 mg and 9 mg nerandomilast groups had smaller degrees of FVC decline vs. placebo in the U.S. subgroup ...

Hypothyroidism is a significant risk factor for IPF, with a higher prevalence in IPF patients compared to the general population. Mendelian randomization confirmed the association between ...